Ubiquitin-specific protease 22 controls melanoma metastasis and vulnerability to ferroptosis through targeting SIRT1/PTEN/PI3K signaling

Abstract

Metastasis is a major contributing factor that affects the prognosis of melanoma patients. Nevertheless, the underlying molecular mechanisms involved in melanoma metastasis are not yet entirely understood. Here, we identified ubiquitin-specific protease 22 (USP22) as a pro-oncogenic protein in melanoma through screening the survival profiles of 52 ubiquitin-specific proteases (USPs). USP22 demonstrates a strong association with poor clinical outcomes and is significantly overexpressed in melanoma. Ablation of USP22 expression remarkably attenuates melanoma migration, invasion, and epithelial–mesenchymal transition in vitro and suppresses melanoma metastasis in vivo. Mechanistically, USP22 controls melanoma metastasis through the SIRT1/PTEN/PI3K pathway. In addition, we conducted an United States Food and Drug Administration-approved drug library screening and identified topotecan as a clinically applicable USP22-targeting molecule by promoting proteasomal degradation of USP22. Finally, we found that both pharmacological and genetic silence of USP22 sensitize RSL3-induced ferroptosis through suppressing the PI3K/Akt/mTOR pathway and its downstream SCD, and ferroptosis inhibitor could partly rescued the decreased lung metastasis by topotecan in vivo. Overall, our findings reveal a prometastatic role of USP22 and identify topotecan as a potent USP22-targeting drug to limit melanoma metastasis.

Keywords

ferroptosis / melanoma / metastasis / topotecan / USP22

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

[2] Xiong K, Qi M, Stoeger T, Zhang J, Chen S. The role of tumor-associated macrophages and soluble mediators in pulmonary metastatic melanoma. Front Immunol. 2022; 13: 1000927.

[3] Millet A, Martin AR, Ronco C, Rocchi S, Benhida R. Metastatic melanoma: insights into the evolution of the treatments and future challenges. Med Res Rev. 2017; 37(1): 98-148.

[4] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1): 17-48.

[5] Villani A, Potestio L, Fabbrocini G, Troncone G, Malapelle U, Scalvenzi M. The treatment of advanced melanoma: therapeutic update. Int J Mol Sci. 2022; 23(12).

[6] Rebecca VW, Somasundaram R, Herlyn M. Pre-clinical modeling of cutaneous melanoma. Nat Commun. 2020; 11(1): 2858.

[7] Klobuch S, Seijkens TTP, Schumacher TN, Haanen J. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat Rev Clin Oncol. 2024; 21(3): 173-184.

[8] Ohanna M, Biber P, Deckert M. Emerging role of deubiquitinating enzymes (DUBs) in melanoma pathogenesis. Cancers (Basel). 2022; 14(14).

[9] Han S, Wang R, Zhang Y, et al. The role of ubiquitination and deubiquitination in tumor invasion and metastasis. Int J Biol Sci. 2022; 18(6): 2292-2303.

[10] He M, Zhou Z, Wu G, Chen Q, Wan Y. Emerging role of DUBs in tumor metastasis and apoptosis: therapeutic implication. Pharmacol Ther. 2017; 177: 96-107.

[11] Guo W, Ma J, Pei T, et al. Up-regulated deubiquitinase USP4 plays an oncogenic role in melanoma. J Cell Mol Med. 2018; 22(5): 2944-2954.

[12] Su D, Wang W, Hou Y, et al. Bimodal regulation of the PRC2 complex by USP7 underlies tumorigenesis. Nucleic Acids Res. 2021; 49(8): 4421-4440.

[13] Xiang M, Liang L, Kuang X, et al. Pharmacological inhibition of USP7 suppresses growth and metastasis of melanoma cells in vitro and in vivo. J Cell Mol Med. 2021; 25(19): 9228-9240.

[14] Feng T, Ling S, Xu C, Ying L, Su D, Xu X. Ubiquitin-specific peptidase 22 in cancer. Cancer Lett. 2021; 514: 30-37.

[15] Zhao Y, Lang G, Ito S, et al. A TFTC/STAGA module mediates histone H2A and H2B deubiquitination, coactivates nuclear receptors, and counteracts heterochromatin silencing. Mol Cell. 2008; 29(1): 92-101.

[16] Qiu GZ, Mao XY, Ma Y, et al. Ubiquitin-specific protease 22 acts as an oncoprotein to maintain glioma malignancy through deubiquitinating B cell-specific Moloney murine leukemia virus integration site 1 for stabilization. Cancer Sci. 2018; 109(7): 2199-2210.

[17] Lin Z, Tan C, Qiu Q, et al. Ubiquitin-specific protease 22 is a deubiquitinase of CCNB1. Cell Discov. 2015; 1: 15028.

[18] Wei Y, Jiang Z, Lu J. USP22 promotes melanoma and BRAF inhibitor resistance via YAP stabilization. Oncol Lett. 2021; 21(5): 394.

[19] Li M, Xu Y, Liang J, et al. USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axis. Mol Ther. 2021; 29(6): 2108-2120.

[20] Zhou Q, Meng Y, Li D, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther. 2024; 9(1): 55.

[21] Meng Y, Sun H, Li Y, et al. Targeting ferroptosis by ubiquitin system enzymes: a potential therapeutic strategy in cancer. Int J Biol Sci. 2022; 18(14): 5475-5488.

[22] Ubellacker JM, Tasdogan A, Ramesh V, et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature. 2020; 585(7823): 113-118.

[23] Ma S, Sun L, Wu W, Wu J, Sun Z, Ren J. USP22 protects against myocardial ischemia-reperfusion injury via the SIRT1-p53/SLC7A11-dependent inhibition of ferroptosis-induced cardiomyocyte death. Front Physiol. 2020; 11: 551318.

[24] Zhang S, Liu X, Wang J, Yuan F, Liu Y. Targeting ferroptosis with miR-144-3p to attenuate pancreatic beta cells dysfunction via regulating USP22/SIRT1 in type 2 diabetes. Diabetol Metab Syndr. 2022; 14(1): 89.

[25] Vandyck HH, Hillen LM, Bosisio FM, van den Oord J, Zur Hausen A, Winnepenninckx V. Rethinking the biology of metastatic melanoma: a holistic approach. Cancer Metastasis Rev. 2021; 40(2): 603-624.

[26] Ghoochani A, Hsu EC, Aslan M, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 2021; 81(6): 1583-1594.

[27] Pedri D, Karras P, Landeloos E, Marine JC, Rambow F. Epithelial-to-mesenchymal-like transition events in melanoma. FEBS J. 2022; 289(5): 1352-1368.

[28] Wei CY, Zhu MX, Yang YW, et al. Downregulation of RNF128 activates Wnt/beta-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma. J Hematol Oncol. 2019; 12(1): 21.

[29] Di Leo L, Bodemeyer V, Bosisio FM, et al. Loss of Ambra1 promotes melanoma growth and invasion. Nat Commun. 2021; 12(1): 2550.

[30] Xu W, Yang Z, Lu N. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr. 2015; 9(4): 317-324.

[31] Ikenoue T, Inoki K, Zhao B, Guan KL. PTEN acetylation modulates its interaction with PDZ domain. Cancer Res. 2008; 68(17): 6908-6912.

[32] Chae HD, Broxmeyer HE. SIRT1 deficiency downregulates PTEN/JNK/FOXO1 pathway to block reactive oxygen species-induced apoptosis in mouse embryonic stem cells. Stem Cells Dev. 2011; 20(7): 1277-1285.

[33] Wang X, Liu M, Zhu MJ, et al. Resveratrol protects the integrity of alveolar epithelial barrier via SIRT1/PTEN/p-Akt pathway in methamphetamine-induced chronic lung injury. Cell Prolif. 2020; 53(3): e12773.

[34] Bu L, Wang H, Pan JA, et al. PTEN suppresses tumorigenesis by directly dephosphorylating Akt. Signal Transduct Target Ther. 2021; 6(1): 262.

[35] Deng G, Zeng F, He Y, et al. EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma. Clin Transl Med. 2022; 12(2): e722.

[36] Meng Y, Sun HY, He Y, et al. BET inhibitors potentiate melanoma ferroptosis and immunotherapy through AKR1C2 inhibition. Mil Med Res. 2023; 10(1): 61.

[37] Hadian K, Stockwell BR. The therapeutic potential of targeting regulated non-apoptotic cell death. Nat Rev Drug Discov. 2023; 22(9): 723-742.

[38] Yin M, Guo Y, Hu R, et al. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction. Nat Commun. 2020; 11(1): 1833.

[39] Deng G, Zeng F, Su J, et al. BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway. Theranostics. 2020; 10(25): 11428-11443.

[40] Zeng F, Li Y, Meng Y, et al. BET inhibitors synergize with sunitinib in melanoma through GDF15 suppression. Exp Mol Med. 2023; 55(2): 364-376.

[41] Zeng F, GD L, Ye Y, et al. Lorlatinib sensitizes melanoma to ferroptosis by targeting IGF1R-mediated PI3K/AKT/mTOR signaling axis.

[42] Cruz L, Soares P, Correia M. Ubiquitin-specific proteases: players in cancer cellular processes. Pharmaceuticals (Basel). 2021; 14(9).

[43] Meliso FM, Micali D, Silva CT, et al. SIRT1 regulates Mxd1 during malignant melanoma progression. Oncotarget. 2017; 8(70): 114540-114553.

[44] Meng Z, Jia LF, Gan YH. PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition. Oncogene. 2016; 35(18): 2333-2344.

[45] Morgan M, Ikenoue T, Suga H, Wolberger C. Potent macrocycle inhibitors of the human SAGA deubiquitinating module. Cell Chem Biol. 2022; 29(4): 544-554. e4.

[46] Montauti E, Weinberg SE, Chu P, et al. A deubiquitination module essential for T(reg) fitness in the tumor microenvironment. Sci Adv. 2022; 8(47): eabo4116.

[47] Zhang Y, Song J, Zhou Y, et al. Discovery of selective and potent USP22 inhibitors via structure-based virtual screening and bioassays exerting anti-tumor activity. Bioorg Chem. 2023; 141: 106842.

[48] Kozicka Z, Thomä NH. Haven’t got a glue: protein surface variation for the design of molecular glue degraders. Cell Chem Biol. 2021; 28(7): 1032-1047.

[49] Alshammari MK, Alghazwni MK, Alharbi AS, et al. Nanoplatform for the delivery of topotecan in the cancer milieu: an appraisal of its therapeutic efficacy. Cancers (Basel). 2022; 15(1).

[50] Nakashio A, Fujita N, Rokudai S, Sato S, Tsuruo T. Prevention of phosphatidylinositol 3’-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res. 2000; 60(18): 5303-5309.

[51] Khorsandi K, Esfahani H, Ghamsari SK, Lakhshehei P. Targeting ferroptosis in melanoma: cancer therapeutics. Cell Commun Signal. 2023; 21(1): 337.

[52] Li Y, Ran Q, Duan Q, et al. 7-Dehydrocholesterol dictates ferroptosis sensitivity. Nature. 2024; 626(7998): 411-418.

[53] Yi J, Zhu J, Wu J, Thompson CB, Jiang X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Nat Acad Sci USA. 2020; 117(49): 31189-31197.

[54] Modi A, Vai S, Caramelli D, Lari M. The illumina sequencing protocol and the NovaSeq 6000 system. Methods Mol Biol. 2021; 2242: 15-42.

[55] He Y, Dong Y, Chen Y, et al. Multi-omics characterization and therapeutic liability of ferroptosis in melanoma. Signal Transduct Target Ther. 2022; 7(1): 268.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.